Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,742,812.50 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 31,250 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $55.77, for a total value of $1,742,812.50. Following the sale, the insider now directly owns 170,237 shares of the company’s stock, valued at approximately $9,494,117.49. This represents a 15.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Tuesday, December 10th, Timothy Rolph sold 4,818 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.91, for a total transaction of $148,924.38.

Akero Therapeutics Stock Performance

Shares of AKRO opened at $55.36 on Friday. The company has a 50-day moving average of $29.78 and a two-hundred day moving average of $28.69. The stock has a market cap of $3.86 billion, a P/E ratio of -14.76 and a beta of -0.19. Akero Therapeutics, Inc. has a 12-month low of $15.32 and a 12-month high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). As a group, research analysts predict that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP increased its stake in Akero Therapeutics by 54.4% in the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock valued at $226,554,000 after purchasing an additional 2,782,029 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Akero Therapeutics during the 3rd quarter valued at about $37,392,000. SG Americas Securities LLC lifted its holdings in shares of Akero Therapeutics by 4,022.1% during the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock worth $16,636,000 after acquiring an additional 583,486 shares during the period. RTW Investments LP grew its holdings in Akero Therapeutics by 9.0% in the third quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock valued at $169,829,000 after purchasing an additional 487,450 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in Akero Therapeutics by 2.9% in the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock valued at $203,053,000 after purchasing an additional 201,225 shares during the period.

Analyst Ratings Changes

AKRO has been the subject of several analyst reports. Bank of America raised shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $35.00 to $63.00 in a report on Thursday. Canaccord Genuity Group raised their price target on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright upped their price objective on Akero Therapeutics from $50.00 to $72.00 and gave the stock a “buy” rating in a report on Monday. Morgan Stanley raised their target price on Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Citigroup increased their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $66.29.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.